Senores Pharmaceuticals is the world's leading research-driven pharmaceutical firm with a presence in several nations, engaged in the research and development, as well as manufacture of a myriad of pharmaceuticals products. The firm has thus built an independent niche in a regulated marketplace in US and Canada besides maintaining robust performance in emerging markets within 43 countries.

Senores Pharmaceuticals has strategically focused on specialty, underpenetrated, and complex pharmaceutical products and has emerged as the preferred partner for top-tier Indian and foreign pharmaceutical companies such as Prasco LLC, Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., Alkem Laboratories, Sun Pharmaceuticals, Dr. Reddy's Laboratories Inc., and Cipla USA Inc.

The company has capabilities in a variety of therapeutic areas and multiple dosage forms, from the manufacturing of critical care injectables and APIs. Senores Pharmaceuticals possesses a fast-growing portfolio with 182 products registered as of March 31, 2024, and a further 245 filings ongoing.

Senores Pharmaceuticals with 113 employees operating by working lean yet efficiently keeps the innovation, regulatory compliance as well as quality manufacturing along with high-value pharmaceutical solutions delivering. Its commitment to research development and partnerships makes it very key in advancing healthcare solution across global markets.

This IPO is going to be an exciting stage for the company, aiming at the strengthening of its position in the market, product development, and exploitation of growing opportunities within the global pharmaceutical sector.